| abstract |
Disclosed is a novel biaryl-piperidine-4-ylidene-methylbenzimidazole derivative compound having MCH antagonist activity. The invention relates to a compound of formula (I) wherein Ar, X, R 1 and R 11 are defined herein, wherein said compound is a novel antagonist to melanin-concentrating hormone (MCH), As well as methods for preparing the compounds. In another embodiment, the present invention provides a pharmaceutical composition comprising such an MCH antagonist and the composition for the treatment of obesity, metabolic disorders, eating disorders such as bulimia, and diabetes. The method used is disclosed. [Selection figure] None |